<?xml version="1.0" encoding="UTF-8"?>
<ref id="cas13513-bib-0009">
 <label>9</label>
 <mixed-citation publication-type="journal" id="cas13513-cit-0009">
  <string-name>
   <surname>Pro</surname>
   <given-names>B</given-names>
  </string-name>, 
  <string-name>
   <surname>Advani</surname>
   <given-names>R</given-names>
  </string-name>, 
  <string-name>
   <surname>Brice</surname>
   <given-names>P</given-names>
  </string-name>, et al. 
  <article-title>Brentuximab vedotin (SGN‐35) in patients with relapsed or refractory systemic anaplastic large‐cell lymphoma: results of a phase II study</article-title>. 
  <source>J Clin Oncol</source>. 
  <year>2012</year>;
  <volume>30</volume>:
  <fpage>2190</fpage>‐
  <lpage>2196</lpage>.
  <pub-id pub-id-type="pmid">22614995</pub-id>
 </mixed-citation>
</ref>
